Annual report pursuant to Section 13 and 15(d)

Stock Based Compensation

v3.24.0.1
Stock Based Compensation
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
10.
Stock-Based Compensation

In connection with the Closing, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“2021 ESPP”). The number of shares available for issuance under the 2021 Plan is increased on the first day of each fiscal year, beginning on January 1, 2022, in an amount equal to the lesser of (i) 2,994,000 shares of Class A common stock, (ii) a number of shares of Class A common stock equal to 5% of the total number of shares of all of Class A common stock outstanding as of the last day of the immediately preceding fiscal year, or (iii) such number of shares of Class A common stock as the Company’s board of directors or its designated committee may determine no later than the last day of the immediately preceding fiscal year.

The 2021 Plan permits the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards to employees, directors, or consultants under the 2021 Plan. Under the 2021 ESPP, the Company can grant stock options to employees to purchase shares of Class A common stock at a purchase price which equals 85% of the lower of (i) the fair market value of Class A common stock on the first trading day of the offering period or (ii) the fair market value of Class A common stock on the exercise date. As of December 31, 2023, 717,543 and 532,686 shares were available for grant under the 2021 Plan and 2021 ESPP, respectively.

The following table summarizes stock option activity under the Company's equity compensation plans:

 

 

Number of
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term

 

 

 

 

 

 

 

 

(in years)

 

Options outstanding as of December 31, 2022

 

 

2,389,622

 

 

$

18.52

 

 

 

6.1

 

Granted

 

 

61,446

 

 

$

5.37

 

 

 

 

Exercised

 

 

(500

)

 

$

7.04

 

 

 

 

Forfeited, canceled, or expired

 

 

(252,016

)

 

$

27.62

 

 

 

 

Options outstanding as of December 31, 2023

 

 

2,198,552

 

 

$

17.11

 

 

 

5.0

 

Vested and expected to vest at December 31, 2023

 

 

2,198,552

 

 

$

17.11

 

 

 

5.0

 

Exercisable at December 31, 2023

 

 

1,901,002

 

 

$

16.91

 

 

 

4.6

 

 

The aggregate intrinsic value of options exercised during 2023 and 2022, was $1 and $483, respectively. The aggregate fair value of options vested during 2023 and 2022 was $3,729 and $6,072, respectively. The Company received $3 and $806 in cash proceeds from options exercised during the years ended December 31, 2023 and 2022, respectively. The weighted-average grant date fair value of options granted for the years ending December 31, 2023 and 2022 was $2.77 and $0.95, respectively. The aggregate intrinsic value of options outstanding as of

December 31, 2023 and 2022 was $387 and $200, respectively. The aggregate intrinsic value of options exercisable as of December 31, 2023 and 2022 was $236 and $200, respectively.

The following table summarizes stock RSU activity under the 2021 Plan:

 

 

 

 

 

Number of RSUs

 

 

Weighted Average Grant Date Fair Value per Share

 

Outstanding as of December 31, 2022

 

 

 

 

1,547,256

 

 

$

19.60

 

RSUs granted

 

 

 

 

1,447,101

 

 

$

5.60

 

RSUs vested

 

 

 

 

(781,557

)

 

$

17.97

 

RSUs forfeited

 

 

 

 

(365,217

)

 

$

15.70

 

Outstanding as of December 31, 2023

 

 

 

 

1,847,583

 

 

$

10.17

 

 

For RSUs with service-based vesting conditions, the fair value is calculated based upon the Company’s closing stock price on the date of grant, and the stock-based compensation expense is recognized over the four-year vesting period.

As of December 31, 2023, there was $19,407 of total unrecognized compensation expense related to options and RSUs expected to be recognized over a weighted average-period of 2.17 years.

The following table summarizes the components of total stock-based compensation expense based on roles and responsibilities of the employees within the consolidated statements of operations:

 

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

Cost of revenue

 

$

197

 

 

$

232

 

Research and development

 

 

3,474

 

 

 

3,154

 

Sales and marketing

 

 

2,707

 

 

 

2,822

 

General and administrative

 

 

6,600

 

 

 

5,283

 

 

$

12,978

 

 

$

11,491

 

 

The fair value of stock-based compensation for stock options was estimated using the Black-Scholes option-pricing model requiring the use of subjective valuation assumptions and inputs, including the expected stock price volatility. The Company’s options have characteristics significantly different from those of traded options, and changes in input assumptions can materially affect the fair value estimates. Stock-based compensation expense for options is recognized over their respective vesting period, which ranges from one to four years.

The fair value of stock options was estimated using the following assumptions at the date of the grant:

 

 

 

Year Ended December 31,

 

2023

 

2022

Risk-free interest rate

 

4.1%

 

2.9%

Expected volatility factor

 

51.8%

 

58.3%

Expected option life

 

5.5 years

 

5.5 years

Expected dividend yield